308 related articles for article (PubMed ID: 29479631)
1. Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Prytuła A; van Gelder T
Pediatr Nephrol; 2019 Jan; 34(1):31-43. PubMed ID: 29479631
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
3. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
Berger FA; Mulder MB; Ten Bosch-Dijksman W; van Schaik RHN; Coenen S; de Winter BCM
Br J Clin Pharmacol; 2019 Aug; 85(8):1852-1854. PubMed ID: 31190414
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
[TBL] [Abstract][Full Text] [Related]
7. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
[TBL] [Abstract][Full Text] [Related]
8. NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.
Bremer S; Vethe NT; Skauby M; Kasbo M; Johansson ED; Midtvedt K; Bergan S
Br J Clin Pharmacol; 2017 Nov; 83(11):2494-2502. PubMed ID: 28686294
[TBL] [Abstract][Full Text] [Related]
9. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
van Gelder T; Hesselink DA
Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
[TBL] [Abstract][Full Text] [Related]
10. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
11. Wuzhi Tablet (
Li J; Chen S; Qin X; Fu Q; Bi H; Zhang Y; Wang X; Liu L; Wang C; Huang M
Drug Metab Dispos; 2017 Nov; 45(11):1114-1119. PubMed ID: 28864749
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence.
Vicari-Christensen M; Repper S; Basile S; Young D
Prog Transplant; 2009 Sep; 19(3):277-84. PubMed ID: 19813492
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.
Rojas L; Neumann I; Herrero MJ; Bosó V; Reig J; Poveda JL; Megías J; Bea S; Aliño SF
Pharmacogenomics J; 2015 Feb; 15(1):38-48. PubMed ID: 25201288
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
17. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
18. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.
de Jonge H; Vanhove T; de Loor H; Verbeke K; Kuypers DR
Br J Clin Pharmacol; 2015 Sep; 80(3):548-59. PubMed ID: 26114223
[TBL] [Abstract][Full Text] [Related]
19. The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients.
Schijvens AM; van Hesteren FHS; Cornelissen EAM; Bootsma-Robroeks CMHHT; Brüggemann RJM; Burger DM; de Wildt SN; Schreuder MF; Ter Heine R
Pediatr Nephrol; 2019 Mar; 34(3):507-515. PubMed ID: 30374607
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
Coto E; Tavira B
Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
